(RTTNews) - argenx SE (ARGX), a Dutch immunology company, reported Thursday that its first-quarter loss attributable to owners of the parent widened to $61.60 million from last year's loss of $28.87 million.
Loss per share was $1.04, compared to loss of $0.52 per share a year ago. Analysts on average expected the company to report loss of $0.76 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
Total operating expenses for the three months were $506 million, compared to $334 million for the same period in 2023.
Total operating income climbed to $412.51 million from prior year's $229.88 million. The Street was looking for revenues of $405.78 million.
Product net sales of VYVGART and VYVGART SC for the period were $398 million, compared to $218 million for the same period in 2023.
The company further announced that Brian Kotzin has been appointed as non-executive director to the Board of Directors and Chair of the Research & Development Committee for a term of four years.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
